Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Colposcopically and biopsy confirmed grade 3 cervical intraepithelial neoplasia~  * Human papillomavirus (HPV) 16-positive disease by PCR~* Measurable disease after diagnostic biopsy~* No concurrent adenocarcinoma in situ of the cervix~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use an effective form of contraception during study treatment~* Immunocompetent~* No concurrent malignancy, except for nonmelanoma skin lesions~* No serious concurrent disorder, including any of the following:~  * Active systemic infection~ * Autoimmune disease~ * Proven or suspected immunosuppressive disorder~ * Major medical illnesses of the cardiovascular or respiratory system~* No evidence or history of cardiac disease, including any of the following:~  * Congestive heart failure~ * Symptomatic arrhythmia not controlled by medication~ * Unstable angina~ * History of acute myocardial infarction or cerebrovascular accident within the past 6 months~* No history of severe allergy including eczema or other exfoliative skin disorder~* No active eczema within the past 12 months~* No concurrent skin conditions, including any of the following:~  * Burns~ * Traumatic or pruritic skin conditions~ * Open wounds~ * Unhealed surgical scars~* Patients and their close social, sexual, or domestic contacts may not have any of the following active skin diseases:~  * Psoriasis~ * Lichen planus~ * Sever acneiform rash~ * Impetigo~ * Varicella zoster~ * Sepsis~* No close social contact with children under 5 years old~* No close social or domestic contact with a pregnant woman~* No HIV seropositivity~* No allergy to eggs~PRIOR CONCURRENT THERAPY:~* No previous vaccination with vaccinia~* No immunosuppressive medication (i.e., steroid therapy or other immunosuppressive/immunomodulating drugs \[e.g., cyclosporine\]) within the past 2 months~* No investigational agent(s) within the past 6 months~* No concurrent participation in another experimental protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Groups 1-3 (Type: EXPERIMENTAL): Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
- Group 4 (Type: EXPERIMENTAL): Patients receive topical imiquimod on days 1, 29, and 57.
- Group 5 (Type: EXPERIMENTAL): Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).